Israel Englander’s FibroBiologics FBLG Stock Holding History

Israel Englander’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,425	Closed	-$64.9K	–	6489
2025 Q4	$64.9K	Sell	14,425 -7,885	-35%	-$55.5K	﹤0.01%	5701
2025 Q3	$244K	Sell	22,310 -1,722	-7%	-$20.6K	﹤0.01%	5450
2025 Q2	$299K	Buy	+24,032	New	+$433K	﹤0.01%	5193
2024 Q4	–	Sell	-561	Closed	-$34.7K	–	6546
2024 Q3	$34.7K	Sell	561 -656	-54%	-$43.6K	﹤0.01%	5733
2024 Q2	$122K	Sell	1,217 -9,245	-88%	-$1.76M	﹤0.01%	5270
2024 Q1	$2.26M	Buy	+10,462	New	+$2.52M	﹤0.01%	3623

Other funds holding FBLG

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Israel Englander's FBLG Position: Q1 2026 in Review

Israel Englander sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 14,425 shares — an estimated $64.9K sold.

Israel Englander first reported a position in FBLG in Q1 2024 and held it in 6 quarters. The position peaked at $2.26M in Q1 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Israel Englander reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
Israel Englander sold 14,425 FibroBiologics shares in Q1 2026, an estimated $64.9K.
Israel Englander first reported a position in FibroBiologics in Q1 2024 and held it in 6 quarters.
Israel Englander's FibroBiologics position peaked at $2.26M in Q1 2024.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.